Chapter 10
I read the email three times. Then I close it and open a new window and search for “Merrifield Biopharma funding” and “university grant program” and “Boston clinical trial funding,” and what I find is not a news story — the story hasn’t reached the press yet — but a university budget memo forwarded to department chairs, noting that Merrifield Biopharma’s annual contribution to the clinical-trial methodology program is under internal review following a “restructuring of the company’s philanthropic priorities. ”
Restructuring. The word sits in my inbox like a grenade with the pin still in.
I call Auden.
“Did you see the email?” I ask.
“I got a copy twenty minutes ago. The department chair cc’d the whole committee.”
“It’s the foundation. Langston’s foundation. The clinical-trial philanthropy initiative — the one I designed the methodology for — is being restructured, and the restructuring is affecting the university’s funding.”
“I know what it is, Cal.”
“This is my research program. The adaptive dosing methodology. The framework I built. The NIH grant funds my research, but the university’s infrastructure (the lab space, the computing cluster, the research assistants) is funded by the Merrifield contribution.
If they cut the contribution, the infrastructure goes. If the infrastructure goes —”
“Your research doesn’t stop. You still have the NIH grant. You find alternative infrastructure.”
“I know. But that takes time, and time means delay, and delay means the FDA regulatory conversation stalls, and —” I stop.
I am spiraling, and I know I am spiraling, and the spiraling has a specific, bitter flavor: the taste of my professional life colliding with my personal one in the exact way I have spent three months trying to prevent.
“What happened?” I ask. “Why is the foundation restructuring now?”
Auden is quiet for a moment. I hear her calculating — not the mathematical kind but the social kind, the kind where she weighs how much truth to deliver and in what order.
“The board met last week,” she says. “Cabot ran the meeting. Langston was present but didn’t lead.
The discussion centered on the foundation’s mission alignment — whether the current funding priorities still reflect the Merrifield family’s values.
One of the priorities under review is the clinical-trial philanthropy initiative. ”
“The initiative I built.”
“The initiative you built, funded through the foundation, administered through the university. It’s been the foundation’s flagship program for two years.
But the board — specifically Langston’s mother — raised concerns about the optics.
The founder’s estranged wife designed the methodology.
The founder is in the middle of a divorce.
The program carries both names. She suggested a review period. ”
“Langston’s mother killed my program.”
“She didn’t kill it. She put it under review. There’s a difference.”
“The difference is sixty days and a committee meeting.”
I hang up. I sit at my desk in my campus office and I look at the email and I think about Langston Merrifield, who I have not spoken to since the burn unit, who has been writing therapy notebooks and crying in Auden’s office and delegating his board authority and doing all the work of a man who is trying to change, and who has — through the machinery of his family, his board, his mother’s concern about optics — reached into the one part of my life that has nothing to do with him and disrupted it.
The committee meeting is in the dean’s conference room, which has a long table and bad lighting and the specific atmosphere of a room where careers are shaped by people who have never worked in a lab.
There are eight of us: four faculty members from the biostatistics department, the dean of the school of public health, a representative from the university’s grants office, and two members of the Merrifield Foundation’s advisory committee — one of whom is me, technically, though I haven’t attended a foundation meeting since the fire and don’t intend to attend another.
The dean opens by laying out the facts. Merrifield Biopharma’s annual contribution to the clinical-trial methodology program is one point two million dollars.
The contribution funds lab space, a computing cluster, three research assistant positions, and the administrative support for two active clinical trials.
The foundation’s board has placed the contribution under a sixty-day review, during which the funds are held in escrow.
If the review results in a reduction or cancellation, the university will need to find alternative funding or scale back the program.
“Dr. Merrifield,” the dean says, turning to me, “you designed the clinical-trial methodology framework that the program is built on. You’re the PI on the active trials. What’s your assessment of the impact?”
Every face in the room turns to me. I feel the specific pressure of being the person who knows the most and is the most compromised, and I meet it the way I meet every pressure now — head-on, with data.
“If the contribution is reduced by more than forty percent, the computing cluster becomes unsustainable,” I say.
My voice is steady. My left arm rests on the table in its compression sleeve and nobody looks at it.
“The cluster runs the Bayesian simulations for the adaptive dosing trials. Without it, we can’t process the sequential analysis in real time.
The trials don’t stop, but they slow down significantly.
Months of delay on results that the FDA is waiting for. ”
“And if the contribution is cancelled entirely?”
“We lose the research assistants. The lab space reverts to the department’s general pool. The active trials would need to migrate to a partner institution — probably Harvard or Johns Hopkins — which means I lose PI status and become a collaborator on my own research.”
The room is quiet. The grants office representative writes something on his pad. The dean nods slowly, the nod of a man who is already thinking about phone calls he needs to make.
“Is there any possibility of a direct conversation with the foundation?” the dean asks. “To clarify their timeline and intentions?”
“I can’t have that conversation,” I say. “For obvious reasons.”
The obvious reasons hang in the air. Everyone in this room knows who I’m married to.
Everyone in this room knows about the fire, or at least the version that has traveled through the department — the careful, euphemistic version where a fire destroyed a home and a marriage and the details are left to imagination.
They know that my presence on this committee is complicated.
They know that the foundation’s review is not purely about mission alignment — it’s about a family that is coming apart, and the institutional debris falls on a program I built.
The meeting lasts ninety minutes. The outcome is a task force — because universities solve everything with task forces — charged with identifying alternative funding sources and developing a contingency plan for the computing cluster.
I am appointed to lead the task force because I am the person who understands the infrastructure best, and because nobody else in the room has the technical knowledge to evaluate the options.
After the formal agenda, the conversation drifts.
The grants office representative asks whether Merrifield Biopharma has a history of pulling funding mid-cycle.
I tell him no — the contribution has been renewed annually without interruption for three years.
The dean asks whether I have any insight into the board’s internal dynamics.
I tell him I’m on the advisory committee but have no voting power and have not attended a meeting since August.
“Since the fire,” the dean says. He doesn’t say it unkindly. He says it the way people say facts that they know are loaded — carefully, with a glance at the door to make sure it’s closed.
“Since the fire,” I confirm.
The room recalibrates. I can feel it happening — the shift from institutional problem to personal one, from funding crisis to the story of a marriage that broke and scattered debris across a university’s budget line.
Everyone here is a professional. Everyone here understands that institutional funding is institutional, not personal.
And everyone here also knows that the Merrifield Foundation is a family entity and that the family is fracturing and that the person sitting at this table with a compression sleeve on her left arm is the reason the fracture became visible.
One of the faculty members — Chen, a quantitative geneticist who has shared lab space with me for four years — catches my eye across the table. She doesn’t say anything. She gives a small nod. The nod says: I see you. I see this. I’m sorry it landed here.
I nod back. The nod says: I know. Let’s fix it.
I leave the meeting and I walk across campus in the November cold.
The air is sharp and the sky is the color of pewter and the students move in clusters toward the dining hall and the library and the places where their lives happen without reference to billionaires or fires or the politics of philanthropy.
I walk past the biostatistics building and the student union and the ugly brutalist tower where the administrative offices live, and I keep walking until I reach the edge of campus where there’s a bench near the bus stop and nobody is sitting on it.
I sit. The cold comes through my coat and my compression sleeve and my bones.
I sit on the bench and I feel the anger return — not the hot, immediate anger of the burn unit, not the controlled anger of the divorce proceedings, but something colder and more settled.
The anger of a woman who has spent three months building a life that doesn’t depend on Langston Merrifield and has just been shown that the dependency runs deeper than she knew.